421 related articles for article (PubMed ID: 32479641)
1. Secukinumab shows high and sustained efficacy in nail psoriasis: 2.5-year results from the randomized placebo-controlled TRANSFIGURE study.
Reich K; Sullivan J; Arenberger P; Jazayeri S; Mrowietz U; Augustin M; Elewski B; You R; Regnault P; Frueh JA
Br J Dermatol; 2021 Mar; 184(3):425-436. PubMed ID: 32479641
[TBL] [Abstract][Full Text] [Related]
2. Effect of secukinumab on the clinical activity and disease burden of nail psoriasis: 32-week results from the randomized placebo-controlled TRANSFIGURE trial.
Reich K; Sullivan J; Arenberger P; Mrowietz U; Jazayeri S; Augustin M; Parneix A; Regnault P; You R; Milutinovic M
Br J Dermatol; 2019 Nov; 181(5):954-966. PubMed ID: 30367462
[TBL] [Abstract][Full Text] [Related]
3. Sustained efficacy of secukinumab in patients with moderate-to-severe palmoplantar psoriasis: 2·5-year results from GESTURE, a randomized, double-blind, placebo-controlled trial.
Gottlieb AB; Kubanov A; van Doorn M; Sullivan J; Papp KA; You R; Regnault P; Frueh JA
Br J Dermatol; 2020 Apr; 182(4):889-899. PubMed ID: 31286480
[TBL] [Abstract][Full Text] [Related]
4. Secukinumab demonstrates high efficacy and a favourable safety profile in paediatric patients with severe chronic plaque psoriasis: 52-week results from a Phase 3 double-blind randomized, controlled trial.
Bodemer C; Kaszuba A; Kingo K; Tsianakas A; Morita A; Rivas E; Papanastasiou P; Keefe D; Patekar M; Charef P; Zhang L; Cafoncelli S; Papavassilis C
J Eur Acad Dermatol Venereol; 2021 Apr; 35(4):938-947. PubMed ID: 33068444
[TBL] [Abstract][Full Text] [Related]
5. Secukinumab treatment leads to normalization of quality of life and disease symptoms in psoriasis patients with or without prior systemic psoriasis therapy: the PROSE study results.
Augustin M; Dauden E; Mrowietz U; Konstantinou MP; Gerdes S; Kingo K; Szepietowski JC; Perrot JL; Cuccia A; Rissler M; Gathmann S; Sieder C; Orsenigo R; Jagiello P; Bachhuber T
J Eur Acad Dermatol Venereol; 2021 Feb; 35(2):431-440. PubMed ID: 32426889
[TBL] [Abstract][Full Text] [Related]
6. Long-term efficacy and safety of secukinumab in Japanese patients with moderate to severe plaque psoriasis: 3-year results of a double-blind extension study.
Okubo Y; Ohtsuki M; Morita A; Yamaguchi M; Shima T; Tani Y; Nakagawa H;
J Dermatol; 2019 Mar; 46(3):186-192. PubMed ID: 30672623
[TBL] [Abstract][Full Text] [Related]
7. Secukinumab demonstrates high sustained efficacy and a favourable safety profile in patients with moderate-to-severe psoriasis through 5 years of treatment (SCULPTURE Extension Study).
Bissonnette R; Luger T; Thaçi D; Toth D; Lacombe A; Xia S; Mazur R; Patekar M; Charef P; Milutinovic M; Leonardi C; Mrowietz U
J Eur Acad Dermatol Venereol; 2018 Sep; 32(9):1507-1514. PubMed ID: 29444376
[TBL] [Abstract][Full Text] [Related]
8. Secukinumab provides sustained improvement in nail psoriasis, signs and symptoms of psoriatic arthritis and low rate of radiographic progression in patients with concomitant nail involvement: 2-year results from the Phase III FUTURE 5 study.
Nash P; Mease PJ; Kirkham B; Singhal A; Quebe-Fehling E; Pricop L; Gaillez C
Clin Exp Rheumatol; 2022 May; 40(5):952-959. PubMed ID: 34494957
[TBL] [Abstract][Full Text] [Related]
9. Secukinumab efficacy in the treatment of nail psoriasis: a case series.
Pistone G; Gurreri R; Tilotta G; Castelli E; Bongiorno MR
J Dermatolog Treat; 2018; 29(sup1):21-24. PubMed ID: 30273068
[TBL] [Abstract][Full Text] [Related]
10. Secukinumab 2-weekly vs. 4-weekly dosing in patients with plaque-type psoriasis: results from the randomized GAIN study.
Reich K; Körber A; Mrowietz U; Sticherling M; Sieder C; Früh J; Bachhuber T
Br J Dermatol; 2021 May; 184(5):849-856. PubMed ID: 32652528
[TBL] [Abstract][Full Text] [Related]
11. Secukinumab dosing optimization in patients with moderate-to-severe plaque psoriasis: results from the randomized, open-label OPTIMISE study.
Reich K; Puig L; Szepietowski JC; Paul C; Lacour JP; Tsianakas A; Sieder C; Rissler M; Pournara E; Orsenigo R
Br J Dermatol; 2020 Feb; 182(2):304-315. PubMed ID: 31102257
[TBL] [Abstract][Full Text] [Related]
12. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: Results from the CLEAR study.
Blauvelt A; Reich K; Tsai TF; Tyring S; Vanaclocha F; Kingo K; Ziv M; Pinter A; Vender R; Hugot S; You R; Milutinovic M; Thaçi D
J Am Acad Dermatol; 2017 Jan; 76(1):60-69.e9. PubMed ID: 27663079
[TBL] [Abstract][Full Text] [Related]
13. Rapid response of nail psoriasis to secukinumab in patients with moderate to severe psoriasis after 12 weeks of treatment with a total of 24 weeks of follow-up.
Go GM; Hong YJ; Lee HJ; Kim M
Australas J Dermatol; 2024 May; 65(3):e13-e20. PubMed ID: 38288519
[TBL] [Abstract][Full Text] [Related]
14. Secukinumab efficacy and safety in Japanese patients with moderate-to-severe plaque psoriasis: subanalysis from ERASURE, a randomized, placebo-controlled, phase 3 study.
Ohtsuki M; Morita A; Abe M; Takahashi H; Seko N; Karpov A; Shima T; Papavassilis C; Nakagawa H;
J Dermatol; 2014 Dec; 41(12):1039-46. PubMed ID: 25354738
[TBL] [Abstract][Full Text] [Related]
15. Secukinumab sustains good efficacy and favourable safety in moderate-to-severe psoriasis after up to 3 years of treatment: results from a double-blind extension study.
Bissonnette R; Luger T; Thaçi D; Toth D; Messina I; You R; Guana A; Fox T; Papavassilis C; Gilloteau I; Mrowietz U
Br J Dermatol; 2017 Oct; 177(4):1033-1042. PubMed ID: 28580579
[TBL] [Abstract][Full Text] [Related]
16. Secukinumab long-term efficacy and safety in psoriasis through to year 5 of treatment: results of a randomized extension of the phase III ERASURE and FIXTURE trials.
Langley RG; Sofen H; Dei-Cas I; Reich K; Sigurgeirsson B; Warren RB; Paul C; Szepietowski JC; Tsai TF; Hampele I; You R; Charef P; Papavassilis C
Br J Dermatol; 2023 Feb; 188(2):198-207. PubMed ID: 36763857
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study.
Papp KA; Langley RG; Sigurgeirsson B; Abe M; Baker DR; Konno P; Haemmerle S; Thurston HJ; Papavassilis C; Richards HB
Br J Dermatol; 2013 Feb; 168(2):412-21. PubMed ID: 23106107
[TBL] [Abstract][Full Text] [Related]
18. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial.
Thaçi D; Blauvelt A; Reich K; Tsai TF; Vanaclocha F; Kingo K; Ziv M; Pinter A; Hugot S; You R; Milutinovic M
J Am Acad Dermatol; 2015 Sep; 73(3):400-9. PubMed ID: 26092291
[TBL] [Abstract][Full Text] [Related]
19. Adalimumab for nail psoriasis: Efficacy and safety from the first 26 weeks of a phase 3, randomized, placebo-controlled trial.
Elewski BE; Okun MM; Papp K; Baker CS; Crowley JJ; Guillet G; Sundaram M; Poulin Y; Gu Y; Geng Z; Williams DA; Rich PA
J Am Acad Dermatol; 2018 Jan; 78(1):90-99.e1. PubMed ID: 28993005
[TBL] [Abstract][Full Text] [Related]
20. Secukinumab administration by pre-filled syringe: efficacy, safety and usability results from a randomized controlled trial in psoriasis (FEATURE).
Blauvelt A; Prinz JC; Gottlieb AB; Kingo K; Sofen H; Ruer-Mulard M; Singh V; Pathan R; Papavassilis C; Cooper S;
Br J Dermatol; 2015 Feb; 172(2):484-93. PubMed ID: 25132411
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
